Rank 71 • Biotech & Discovery
Genesis Therapeutics
Develops deep learning models to predict molecular properties and design small-molecule therapeutics for challenging targets.
Visit website- Signal Score
- 84.6
- Total raised
- $280M
- Stage
- Series B
- Founded
- 2019
- Headquarters
- Burlingame, USA
- Region
- North America
Their signal
Genesis Therapeutics stands out in computer-aided drug design, securing major pharma partnerships and venture backing due to its unique ability to model complex, previously undruggable 3D protein structures.
Signal Score 84.6editorial estimate, see how it is built
Total raised, quality of investors and recency of the last round.
Revenue trajectory, customer count, hiring and market pull.
Peer-reviewed evidence, FDA/CE clearances and live health-system deployments.
Founder track record, clinical depth on the bench and technical leadership.
Search presence, press coverage, founder and brand reach, and how often the company shows up where buyers look.
Also in Biotech & Discovery
Figures are subjective research desk estimates compiled from public sources and refreshed daily, published as editorial commentary. Company marks are shown for identification only and imply no endorsement or affiliation. Want a correction, an update or removal? and see our corrections and removals policy.